Capoten 5 mg ml - Capoten (Captopril): Side Effects, Interactions, Warning, Dosage & Uses
The high dose in these studies is times the maximum recommended human dose of mg, assuming a kg capoten. On a body-surface-area basis, the high doses for mice and rats are 13 and 26 times the maximum recommended human dose, respectively. Studies in rats have revealed no impairment of fertility. Animal Toxicology Chronic oral toxicity studies were conducted in rats 2 yearsdogs 47 weeks; 1 yearmice 2 yearsand monkeys 1 year.
On a body-surface-area basis, these doses are 5 to 25 times maximum recommended dose MRHD. Anemia, leukopenia, thrombocytopenia, and bone marrow suppression occurred in dogs at doses 8 to 30 times MRHD on a body-weight basis 4 to 15 times MRHD on a surface-area basis. The reductions in hemoglobin and hematocrit values in rats and mice were only significant at 1 year and returned to normal with continued dosing by the end of the study.
The anemia could be reversed upon discontinuation of dosing. Bone marrow suppression occurred to a varying degree, being associated only with dogs that died or were sacrificed in a moribund condition in the 1 year study. However, in the week study at a dose 30 times MRHD, bone marrow suppression was found to be reversible upon continued drug administration.
Captopril caused hyperplasia of the juxtaglomerular apparatus of the kidneys in mice and rats at doses 7 to times MRHD on a body-weight basis 0. Rabbits developed gastric and intestinal ulcers when given oral doses approximately 30 times MRHD on a body-weight basis 10 times MRHD on surface-area basis for only 5 to 7 days.
In the two-year rat study, capoten 5 mg ml, irreversible and progressive variations in the caliber of retinal vessels focal sacculations and constrictions occurred at all dose levels 7 to times MRHD on a body-weight basis; 1 to 35 times MRHD on a surface-area basis in a dose-related fashion. The effect was first observed in the 88th week capoten dosing, with a progressively increased incidence thereafter, even after cessation of dosing.
Nursing Mothers Concentrations of captopril in human milk are approximately one percent capoten those in maternal blood. Because of the potential for serious adverse reactions in nursing infants from captopril, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of Capoten to the mother. Pediatric Use Safety and effectiveness in pediatric patients have not been established.
There is limited experience reported in the literature with the use of captopril in the pediatric population; dosage, on a weight basis, capoten 5 mg ml, was generally reported to be comparable to or less than that used in adults. Infants, especially newborns, may be more susceptible to the adverse hemodynamic effects of captopril.
Excessive, prolonged and unpredictable decreases in blood pressure and associated complications, including oliguria and seizures, have been reported. Capoten should be used in pediatric patients only if other measures for controlling blood capoten have not been effective. Adverse Reactions Reported incidences are based annual sales of lipitor 2010 clinical trials involving approximately patients.
Each of the following has been reported in approximately 1 to 2 of patients and are of uncertain relationship to drug use: Cases of anemia, thrombocytopenia, and pancytopenia have been reported. Rash, capoten 5 mg ml, often with pruritus, and sometimes with fever, arthralgia, and eosinophilia, occurred in about 4 to 7 depending on renal status and dose of patients, usually during the first four weeks of therapy. It is usually maculopapular, and rarely urticarial.
Pruritus, without rash, occurs in about 2 of patients. A reversible associated pemphigoid-like lesion, and capoten, have also brand viagra on sale reported.
Flushing or pallor has been reported in 2 to 5 of patients. Tachycardia, chest pain, and palpitations have each been observed capoten approximately 1 of patients.
Approximately 2 to 4 depending on renal status and dose of patients developed a diminution capoten loss of taste perception. Taste impairment is reversible and usually self-limited 2 to 3 months even with continued drug administration, capoten 5 mg ml. Weight loss may be associated with the loss of taste.
Angioedema involving the extremities, face, lips, mucous membranes, capoten 5 mg ml, tongue, glottis or larynx has been reported in approximately one in patients. Angioedema involving the upper airways has caused fatal airway obstruction.
Cough has been reported in 0. Capoten following have been reported in about 0.
Other clinical adverse effects reported since the drug was marketed are listed below by body system. In this setting, an incidence or causal relationship cannot be accurately determined.
Capoten Dosage
Body as a whole: Bullous pemphigus, capoten 5 mg ml, erythema multiforme including Stevens-Johnson syndromeexfoliative dermatitis. Anemia, including aplastic and hemolytic. Jaundice, hepatitis, including rare cases of necrosis, cholestasis. Ataxia, confusion, depression, nervousness, somnolence. Bronchospasm, eosinophilic pneumonitis, rhinitis. As with other ACE inhibitors, a syndrome has been reported which may include: Capoten Laboratory findings Serum Electrolytes: Transient elevations of BUN or serum creatinine especially in volume or salt depleted patients or those with renovascular hypertension may occur.
Rapid reduction of longstanding or markedly elevated blood pressure can result in decreases in the glomerular filtration rate and, in turn, lead to increases in BUN or serum creatinine. A positive ANA has been reported. Capoten of liver transaminases, alkaline phosphatase, and serum bilirubin have occurred. Overdosage Correction of hypotension would be of primary concern, capoten 5 mg ml. Volume expansion with an intravenous infusion of normal saline is the treatment of choice for restoration of blood pressure.
Capoten Dosage and Administration Capoten should be taken one hour before meals. Dosage must be individualized. Initiation of therapy requires consideration of recent antihypertensive drug treatment, the extent of blood pressure elevation, salt restriction, and other clinical circumstances, capoten 5 mg ml. The initial dose of Capoten captopril tablets, USP is 25 mg b. If satisfactory reduction of blood capoten has not been achieved after one or two weeks, the dose may be increased to 50 mg b.
Concomitant sodium restriction may be beneficial when Capoten is used alone.
Capoten tablets 25 mg
The dose of Capoten in hypertension usually does not exceed 50 mg t. Therefore, if the blood pressure has not been satisfactorily controlled after one to two weeks at this dose, and the patient is not already receiving a diureticcapoten 5 mg ml, a modest dose of a thiazide-type diuretic e.
The diuretic dose may be increased at one- to two-week intervals until its highest usual antihypertensive dose is reached. Drug Interactions regarding hypotensioncapoten 5 mg ml, with dosage and titration of Capoten as noted above. If further blood pressure reduction is required, the dose of Capoten may be increased to mg b. The usual dose range is 25 to mg b.
A maximum daily dose of mg Capoten should not be exceeded. For patients with severe hypertension e. In this regimen, addition of a more potent diuretic, e. Capoten Interactionsbut the effects of the two drugs are less than additive. Hypotension ; for these patients, titration to the usual daily dosage can then occur within the next several days. For most patients the usual initial daily dosage is 25 mg t. After a dose of 50 mg t.
Most patients studied have had capoten satisfactory clinical improvement at 50 or mg t. A maximum daily dose of mg of Capoten should not be exceeded. Capoten should generally be used in conjunction with a diuretic and digitalis. Capoten therapy must be initiated under very close medical supervision. The recommended dose for long-term use in patients following a myocardial infarction is a target maintenance dose of 50 mg t. Therapy may be initiated as early as three days following a myocardial infarction, capoten 5 mg ml.
After a single dose of 6. Capoten should then be increased to 25 mg t. Capoten may be used in patients treated with other post-myocardial infarction therapies, e. The recommended dose of Capoten for long term use to treat diabetic nephropathy is 25 mg t. Other antihypertensives such as diuretics, beta blockers, centrally acting agents or vasodilators may be used in conjunction with Capoten if additional capoten is required to further lower blood pressure.
Dosage Adjustment in Renal Impairment: Because Capoten is excreted primarily by the kidneys, excretion rates can you buy viagra over counter usa reduced in patients with impaired renal function. These patients will take longer to reach steady-state captopril levels and will reach higher steady-state levels for a given daily dose than patients with normal renal function.
Therefore, these patients may respond to smaller or less frequent doses. Accordingly, for patients with significant renal impairment, initial daily dosage of Capoten should be reduced, and smaller increments utilized for titration, which should be quite slow one- to two-week intervals. After the desired therapeutic effect has been achieved, the dose should be slowly back-titrated to determine the minimal effective dose. When concomitant diuretic therapy is required, a loop diuretic e.
Bottles contain a desiccant-charcoal canister. All captopril tablets are white and may exhibit a slight sulfurous odor. Angioedema involving the tongue, glottis or larynx may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, which may include subcutaneous epinephrine solution 1: The patient should be hospitalised and observed for at least 12 to 24 hours and should not be discharged until complete resolution of symptoms has occurred.
Black patients receiving ACE inhibitors have capoten reported to have a higher incidence of angioedema compared to non-blacks. Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor see section 4.
Intestinal angioedema has also been reported rarely in patients treated with ACE inhibitors, capoten 5 mg ml. These patients presented with abdominal pain with or without nausea or vomiting ; in some cases there was no prior facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan, capoten 5 mg ml, or ultrasound or at surgery and symptoms resolved after stopping the ACE inhibitor.
Intestinal angioedema should be included in the differential diagnosis of patients on Coupons for evista inhibitors presenting with abdominal pain see section 4.
Characteristically, the cough is non-productive, persistent and resolves after discontinuation of therapy. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up. Patients at risk for the development of hyperkalaemia include those with renal insufficiency, diabetes mellitus, or those using concomitant potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes; or those patients taking other drugs associated with increases in serum potassium e.
If concomitant use of the above mentioned agents is deemed appropriate, regular monitoring of serum potassium is recommended. Capoten is not recommended in association with lithium due to the potentiation of lithium toxicity see section 4. ACE inhibitors should be used with caution in patients with left ventricular valvular and outflow tract obstruction and avoided in cases of cardiogenic shock and haemodynamically significant obstruction.
In patients with normal renal function and no other complicating factors, neutropenia occurs rarely. Captopril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, capoten 5 mg ml, or a combination of these complicating factors, especially if there is pre-existing impaired renal function.
Some of these patients developed serious infections which in a few instances did not respond to intensive antibiotic therapy. If captopril is used in such patients, it is advised that white blood cell count and differential counts should be performed prior to therapy, every 2 weeks during the first 3 months of captopril therapy, and periodically thereafter.
During treatment all patients should be instructed to report any sign of infection e. Captopril and other concomitant medication see section 4. In most patients neutrophil counts rapidly return to normal upon discontinuing captopril.
Total urinary proteins greater than 1 g per day were seen in about 0.
CAPOTEN TABLETS 25 mg
Nephrotic syndrome occurred in about one-fifth of proteinuric patients. In most cases, proteinuria subsided or cleared within capoten months whether or not captopril was continued.
Parameters of renal function, capoten 5 mg ml, such as BUN and creatinine, were seldom altered in the patients with proteinuria. Patients with prior renal disease should have urinary protein estimations dip-stick on first morning urine prior to treatment, and periodically thereafter. Anaphylactoid reactions during desensitisation: In the same patients, capoten 5 mg ml, these reactions were avoided when the ACE inhibitor was temporarily withheld, but they reappeared upon inadvertent rechallenge, capoten 5 mg ml.
Therefore, caution should be used in patients treated with ACE inhibitors undergoing such desensitisation procedures. In these patients, consideration should be given to using a different type capoten dialysis, membrane or a different class of medication. If hypotension occurs, it may be corrected by volume expansion.
Do not start a new medication without telling your doctor. Where can I get more information? Your pharmacist can provide more information about captopril. Remember, keep this and all other medicines out of the capoten of children, never share your medicines with others, and use this medication only for the indication prescribed. Every effort has been made to ensure that the information provided by Cerner Multum, Inc.
Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United Capoten and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise, capoten 5 mg ml. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient.